Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.

Chunmeng WangYang LiuLiang DongXiang LiQingming YangMalcolm V BrockQian MeiJiejie LiuMeixia ChenFengxia ShiMiao LiuJing NieWeidong Han

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Decitabine plus camrelizumab is associated with high response rates and long-term benefits in patients with relapsed/refractory cHL who failed PD-1 inhibitors.

Keyphrases

hodgkin lymphoma
acute myeloid leukemia
combination therapy
open label
clinical trial
acute lymphoblastic leukemia
randomized controlled trial
diffuse large b cell lymphoma